Historically, classic biotech companies developed monoclonal antibodies and proteins as new therapies for hard-to-treat conditions. There have been multiple examples of blockbuster successes (e.g., EPO, anti-TNF antibodies, HGH, human insulin, etc.) leading the past 30+ years to create the Biotechnology sector.
INCY – KNOWS JAKS– RAISING BUY LIMIT & TARGET – INCB039110 Shows Promise with Proof-of-Concept Data in Both Psoriasis & RA, MF Next Up at ASH
September 5, 2013 Below is a pdf for MTSL Issue #762 of the Medical Technology Stock Letter. [gview file=”http://www.bioinvest.com/wp-content/uploads/2013/09/MTSL-762-September-5-2013.pdf” save=”1″]
September 26, 2013 The Life Sciences Report: John McCamant Scans Under the Radar for Promising Biotechs by : Peter Byrne The Life Sciences Report: The medical biotech sector has generally been going great guns in 2013. Is there a seasonal aspect to the overall performance of biotech stocks? Are some seasons preferable to other seasons[…]
The pharmaceutical and biotechnology industries have gone through periods of blockbuster drug classes, which has often resulted in one or more leading drugs catapulting the respective company’s growth rates and, in many cases, market capital, to the very top of the industry.
Nektar’s NKTR-181 Disappoints, Misses Primary Endpoint on Mixed Phase II Data – Preliminary top-line results from a Phase II trial of NKTR-181(‘181) for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis of the knee missed their primary endpoint due to a unusual lack of a placebo rebound. The drug candidate was shown to[…]
August 22, 2013 Below is a pdf for MTSL Issue #761 of the Medical Technology Stock Letter. [gview file=”http://www.bioinvest.com/wp-content/uploads/2013/08/MTSL-761-August-22-2013.pdf” save=”1″]
Biotechs Are Back In Favor Amid Plethora Of Positive Developments Written By Gene Marcial, Contributor It isn’t often that the biotechnology industry gets swamped with plenty of good news, but that’s what has been happening in recent months. Not surprisingly, they have attracted investor interest. A number of new drug approvals, affirmative data, and accelerated[…]
Unlike most Wall Street analysts, we find no need to continue to raise limits/target prices just because a stock has done what we expect it to. Our initial recommendations are based on the stocks not yet discounting what we believe are improving and/or undervalued fundamentals.
September 19, 2013 Below is a pdf for MTSL Issue #763 of the Medical Technology Stock Letter. [gview file=”http://www.bioinvest.com/wp-content/uploads/2013/09/MTSL-763-September-19-20131.pdf” save=”1″]
August 8, 2013 Below is a pdf for MTSL Issue #760 of the Medical Technology Stock Letter. [gview file=”http://www.bioinvest.com/wp-content/uploads/2013/08/MTSL-760-August-8-2013.pdf” save=”1″]
ISIS Presents More Impressive Phase II Data for APOCIII-Rx at NLA – Over the weekend, ISIS presented data on APOCIII-Rx in patients with familial chylomicronemia syndrome (FCS) at the National Lipid Association (NLA) meeting. FCS is a rare disease that only affects 3,000-5,000 patients globally and is characterized by severely high triglyceride (TG) levels. The[…]
